KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. Show more

1167 Massachusetts Avenue, Suite 120, Arlington, MA, 02476, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

346.9M

52 Wk Range

$0.35 - $20.60

Previous Close

$0.38

Open

$0.39

Volume

338,538

Day Range

$0.38 - $0.42

Enterprise Value

8.80M

Cash

21.1M

Avg Qtr Burn

-10.88M

Insider Ownership

0.01%

Institutional Own.

0.77%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
INVELTYS™ (loteprednol etabonate ophthalmic suspension) Details Post-operative ocular inflammation and pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EYSUVIS™ (loteprednol etabonate ophthalmic suspension) Details Dry Eye Disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KPI-012 Details Persistent Corneal Epithelial Defect	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.